MedTrace Logo

COVID-19 and the Brain

NCT04726176 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-04-29

No results posted yet for this study

Summary

The main objective of this project is:

1\. To assess the impact of COVID-19 on the brain and executive functioning.

Twenty adult subjects of UZ Brussels (volunteers), who needed intensive care due to COVID-19 (n=10) or exhibited mild symptoms due to COVID-19 (n=10), will be recruited after hospital discharge. After signing an informed consent the subjects will undergo brain scans (T1, DTI, SWI, DWI, FLAIR MRI and rsfMRI), an emotion regulation task and a neurocognitive test battery. The latter test battery will be performed using an iPad and will test different neurocognitive functions such as memory, abstract thinking, spatial orientation and attention. The duration of the test battery is 18min. The total duration of one trial is estimated at one hour and a half. All tests are planned at the department of Radiology-Magnetic Resonance (UZ Brussel). After three months patients will visit the department of Radiology-Magnetic Resonance a second time for the same experimental trial. Additionally, a matched control group (n = 20; non covid or ICU patients) will be included and undergo the same tests in order to compare the results of the brain scans, emotional regulation task and neurocognitive test battery with results of both Covid-groups. Next to objective data, questionnaires will be filled out, i.e. visual analogue scales of mental and physical fatigue, Profile of Mood States and some additional return to work questions.

Conditions

  • Covid19
  • Brain
  • Neurocognition
  • fMRI

Interventions

BIOLOGICAL

Exposure to COVID-19

To study the exposure of COVID-19 on the brain and executive functioning

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    collaborator OTHER

  • Vrije Universiteit Brussel

    lead OTHER

Principal Investigators

  • Kevin De Pauw, Prof. Dr. · Vrije Universiteit Brussel

Eligibility

Min Age
35 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-30
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04726176 on ClinicalTrials.gov